FILE – This is a file photo from April 30, 2020 showing the Gilead Sciences headquarters in Foster City, California. The maker of a drug shown to shorten recovery time for seriously ill patients with COVID-19 says it will charge $ 2,340 for a typical course of treatment for people covered by government health programs in the United States and other developed countries. . (AP Photo / Ben Margot, file)
OAN press room
UPDATED 10:20 AM PT – Monday, June 29, 2020
Drug maker Gilead launched its pricing plan for the drug COVID-19 Remdesivir.
The company reportedly plans to charge the US government $ 390 per dose, which will cost Medicare patients at least $ 2,300 for the shortest coronavirus treatment cycle.
It will also charge non-government buyers, such as hospitals, $ 520 per dose, which in turn will cost privately insured patients at least $ 3,100 per treatment cycle.
During an interview on Monday, the company’s CEO Daniel O’Day defended the company’s prices.
“The same approach focused on price, and while this drug adds significant value to the health system by reducing hospital days, we decided to price it at a very extraordinary time in a unique way,” he said. “We value it at value, at the price that allows access throughout the developed world.”
Today we announce the price of our investigational antiviral for the treatment of COVID-19. We believe that our unique approach will provide broad and equitable access. Read more from our President and CEO: https://t.co/rrEbrDxrLk. pic.twitter.com/9ElSExqSU3
– Gilead Sciences (@GileadSciences) June 29, 2020
Gilead will start selling Remdesivir on July 1.
